5-MeO-MPMI
Chemical compound
From Wikipedia, the free encyclopedia
5-MeO-MPMI (developmental code name CP-108509), also known as 5-methoxy-N-methyl-(α,N-trimethylene)tryptamine, is a psychedelic drug of the pyrrolidinylmethylindole and cyclized tryptamine families.[1]
- None
 | |
 | |
| Clinical data | |
|---|---|
| Other names | 5-Methoxy-N-methyl-(α,N-trimethylene)tryptamine; CP-108509; CP108509 |
| Drug class | Serotonergic psychedelic; Hallucinogen |
| ATC code |
|
| Legal status | |
| Legal status | |
| Identifiers | |
| |
| CAS Number | |
| PubChem CID | |
| ChemSpider | |
| UNII | |
| ChEMBL | |
| CompTox Dashboard (EPA) | |
| Chemical and physical data | |
| Formula | C15H20N2O |
| Molar mass | 244.338 g·mol−1 |
| 3D model (JSmol) | |
| |
| |
  (what is this?) (verify) | |
Interactions
Pharmacology
Pharmacodynamics
-5-MeO-MPMI.svg)
5-MeO-MPMI produces psychedelic-appropriate responding in animal tests, with similar potency to DOI.[1] It has two enantiomers, with only the (R)-enantiomer being active.[1]
Chemistry
Analogues
Analogues of 5-MeO-MPMI include MPMI, 4-HO-MPMI, 5-fluoro-MPMI, 5-MeO-pyr-T, CP-122288, CP-135807, and eletriptan, among others.
History
5-MeO-MPMI was first developed by the team led by J. E. Macor and colleagues in 1992.[2] It was subsequently investigated by the team led by David E. Nichols from Purdue University in the late 1990s.[1]
Society and culture
Legal status
Canada
5-MeO-MPMI is not a controlled substance in Canada as of 2025.[3]